Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Role of a Multidisciplinary Healthcare Team to Manage Tumor Lysis Syndrome

January 24th 2023

Shared insight on the multidisciplinary management of tumor lysis syndrome and how treatment planning may be adjusted after it is identified.

Pembrolizumab Following ASCT Generates Promising PFS in T-cell Non-Hodgkin Lymphoma

January 23rd 2023

Craig Sauter, MD, discusses the rationale for investigating maintenance pembrolizumab following autologous stem cell transplant in patients with T-cell NHL and explained some of the potential challenges of investigating this regimen in a larger prospective trial in this patient population.

Future of Acute GvHD Prevention

January 20th 2023

A look into the future of acute GvHD prevention and discussing the impact of targeting specific organs to help manage GvHD prevention.

Clinical Implications of the Phase III BMT CTN 1703 Trial

January 20th 2023

Experts review the Phase III BMT CTN 1703 trial and share how the results of this trial might impact their practice and discuss the role of ATG and abatacept in their practice

UK’s MHRA Approves Zanubrutinib for CLL and MZL

January 19th 2023

The Medicines and Healthcare Products Regulatory Agency has approved zanubrutinib in Great Britain for both the treatment of adult patients with chronic lymphocytic leukemia and the treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20–based therapy.

Myeloproliferative Neoplasms: Targeting CALR With Novel Therapy

January 19th 2023

Key opinion leaders on myeloproliferative neoplasms review the potential of CALR as a therapeutic target following data from the ASH 2022 Annual Meeting.

What is the Role of Transplant in Managing Patients With Myelofibrosis?

January 19th 2023

Expert panelists consider the ongoing role of transplant for patients with myelofibrosis and discuss when it is more appropriate to explore systemic therapy options.

Ibrutinib/Prednisone Provides No CR/PR Benefit vs Placebo/Prednisone in cGVHD

January 18th 2023

First-line ibrutinib plus prednisone did not improve response rates compared with placebo plus prednisone in patients with chronic graft-vs-host disease, failing to meet the primary end point of the phase 3 iNTEGRATE trial.

Tools for Risk Stratification and Prognosis in MDS

January 18th 2023

Uwe Platzbecker, MD introduces models commonly used to determine risk status and prognosis, and inform treatment decisions, for patients with MDS.

NCCN Adds Olutasidenib to Guidelines for Relapsed/Refractory, IDH1-Mutant AML

January 18th 2023

Olutasidenib has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology as a recommended targeted therapy for adult patients with relapsed/refractory acute myeloid leukemia with an IDH1 mutation.

MDS: Typical Patient Presentation, Diagnostic Process, and Evolving Terminology

January 18th 2023

Moderator Rami Komrokji, MD, introduces the panel and invites expert pathologist Sanam Loghavi, MD to lead a discussion on the typical patient presentation and diagnostic process in MDS, which was recently renamed as ‘myelodysplastic neoplasms’ in the 2022 5th edition of the World Health Organization (WHO) classification of the disease state.

Unpacking Data From Pivotal Trials in Multiple Myeloma: Shining a Light on the MASTER Trial Evaluating D-KRd

January 18th 2023

In this second episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, discusses the depth of response reported with daratumumab, carfilzomib, lenalidomide, and dexamethasone in transplant-eligible multiple myeloma.

Identification of Tumor Lysis Syndrome: Signs and Symptoms

January 18th 2023

Comprehensive insight on the signs and symptoms that help lead to the identification of tumor lysis syndrome in patients receiving therapy for cancer.

Overview on Tumor Lysis Syndrome: Incidence and Risk Factors

January 18th 2023

Key opinion leaders James Short, MD, and John Reagan, MD, share an overview on the incidence and clinical risk factors of tumor lysis syndrome.

IPSS-M and IPSS-R Tools for Risk Stratification of MDS

January 18th 2023

Amer Zeidan, MBBS, and Rami Komrokji, MD, compare the available IPSS-M and IPSS-R tools for stratifying risk and assessing prognosis in MDS.

Classification Systems for MDS

January 18th 2023

Distinguished experts in hematology discuss the WHO and ICC classification systems for myelodysplastic syndromes (MDS), including recent WHO updates.

FDA Grants Orphan Drug Designation to JBI-802 for Small Cell Lung Cancer and AML

January 16th 2023

The FDA has granted an orphan drug designation to JBI-802 for the treatment of patients with small cell lung cancer and acute myeloid leukemia.

Axi-cel Maintains PFS and ORR Benefit in 3-Year Follow-Up of ZUMA-5 in Indolent NHL

January 16th 2023

Axicabtagene ciloleucel continued to elicit improved progression-free survival and overall response rates in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Zanubrutinib Extends Treatment Duration in Acalabrutinib-Intolerant Patients With B-cell Malignancies

January 16th 2023

Patients with B-cell malignancies who were intolerant to acalabrutinib experienced a longer treatment duration when subsequently receiving zanubrutinib.

Unpacking Data From Pivotal Trials in Multiple Myeloma: Examining Findings From the GRIFFIN Trial of D-RVd

January 13th 2023

In this first episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, provides perspective on the use of daratumumab-based quadruplets as induction therapy in multiple myeloma.